Table 2. General characteristics of outcome-related published studies and microarray datasets.
| Author | Data source | Year | Country | Patients (n) | Test method/Platform | Cut off values | HR estimation | survival analysis | HR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| Kanaji S et al. | PMID:16645325 | 2006 | Japan | 160 | IHC | NR | Multivariate analysis | OS | 2.02 (1.10–3.72) |
| Weichert W et al. | PMID: 16630118 | 2006 | Germany | 135 | IHC | IRS> 6 | Survival curve | OS | 2.09 (1.29-3.41) |
| Otsu H et al. | PMID: 27245623 | 2016 | Japan | 207 | IHC | IRS≥6 | Survival curve | OSRFS | 1.77 (0.93-3.36)1.38 (0.95-2.02) |
| Jang YJ et al. | PMID: 16865274 | 2006 | Korea | 280 | IHC | NR | Survival curve | OS | 0.40 (0.17-0.91) |
| Chen ZW et al | CNKI | 2009 | China | 80 | IHC | Score≥2 | NR | NR | NR |
| Sun YH et al. | CNKI | 2014 | China | 60 | IHC | IOD≥994 | Survival curve | OS | 2.25 (1.21-4.16) |
| Zou CG et al | CNKI | 2009 | China | 49 | IHC | Score≥2 | NR | NR | NR |
| Lan B et al. | PMID: 17253180 | 2007 | China | 89 | IHC | Score>6 | Survival curve | OS | 2.77 (1.09-4.73) |
| Zhang Q et al. | CNKI | 2005 | China | 54 | IHC | Positive cells≥6% | NR | NR | NR |
| Xia D et al. | CNKI | 2014 | China | 80 | IHC | SCORE>1 | NR | NR | NR |
| Yao HL et al. | PMID: 21051833 | 2010 | China | 59 | IHC | Positive cells≥6% | NR | NR | NR |
| TCGA | TCGA | 2017 | USA | 415 | NR | ≥11.95 | Multivariate analysis | OSRFS | 1.25 (0.87-1.78)1.27 (0.93-1.75) |
| Kim HK et al. | GSE14208 | 2011 | USA | 123 | GPL571 | ≥6.67 | Univariate analysis | OSPFS | 1.41 (0.97-2.06)1.47 (1.01-2.14) |
| Ooi CH et al. | GSE15459 | 2014 | Switzerland | 192 | GPL570 | ≥8.38 | Multivariate analysis | OS | 0.95 (0.61-1.50) |
| Paik S et al. | GSE26253 | 2014 | South Korea | 432 | GPL8432 | ≥9.07 | Univariate analysis | RFS | 0.68 (0.51-0.91) |
| Lee J et al (2). | GSE26901 | 2016 | USA | 109 | GPL6947 | ≥7.18 | NR | NR | NR |
| Lee J et al (1). | GSE28541 | 2012 | USA | 40 | GPL13376 | ≥6.81 | NR | NR | NR |
| Lei Z et al. | GSE34942 | 2014 | Singapore | 56 | GPL570 | ≥5.52 | Multivariate analysis | OS | 1.96 (0.73-5.28) |
| Zhang X et al. | GSE63089 | 2014 | China | 45 | GPL5175 | ≥6.79 | NR | NR | NR |
| Cui J et al. | Oncomine | 2011 | USA | 80 | GPL5175 | ≥7.06 | NR | NR | NR |
| Cho JY et al. | Oncomine | 2011 | USA | 65 | GPL6884 | ≥7.07 | NR | NR | NR |
NR: not reported; OS: overall survival; IHC: immunohistochemistry; RFS: recurrence-free survival; IRS: immunoreactivity scoring system; IOD: integrated optical density; PFS: progression-free survival.